Sapanisertib
Sapanisertib
Sapanisertib (pronunciation: sah-pan-ee-ser-tib) is a type of cancer drug that is currently under investigation for its potential therapeutic effects.
Etymology
The name "Sapanisertib" is derived from the pharmaceutical company that developed it, Novartis, and its intended use as an inhibitor (sertib) of certain cellular processes.
Definition
Sapanisertib is an mTOR inhibitor that is being studied in the treatment of various types of cancer. It works by blocking a protein known as mTOR, which is involved in cell growth and survival. By inhibiting this protein, Sapanisertib may slow or stop the growth of cancer cells.
Related Terms
- mTOR inhibitor: A type of drug that blocks the action of mTOR, a protein in cells that is involved in cell growth and survival.
- Cancer: A group of diseases characterized by the uncontrolled growth and spread of abnormal cells.
- Novartis: A multinational pharmaceutical company based in Switzerland that developed Sapanisertib.
Usage
Sapanisertib is currently being studied in clinical trials for its potential use in treating various types of cancer, including lung cancer, breast cancer, and pancreatic cancer. It is not yet approved for use by the Food and Drug Administration (FDA).
See Also
External links
- Medical encyclopedia article on Sapanisertib
- Wikipedia's article - Sapanisertib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski